Gf Fund Management Co. Ltd. Trevi Therapeutics, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $5.51 Trillion
- Q3 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 2,620 shares of TRVI stock, worth $29,684. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,620
Previous 1,968
33.13%
Holding current value
$29,684
Previous $10.8 Million
122.69%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TRVI
# of Institutions
174Shares Held
119MCall Options Held
629KPut Options Held
1.22M-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million7.39% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Viking Global Investors LP5.13MShares$58.1 Million0.13% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...